Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

Cancel

BSE Code : 524404 | NSE Symbol : MARKSANS | ISIN : INE750C01026 | Industry : Pharmaceuticals - Indian - Formulations |

(19-Jun-25 10:04) Marksans Pharma’s UK arm gets marketing nod for Oxybutynin Oral solution from UKMHRA
(30-May-25 09:33) Marksans Pharma gets regulatory nod for marketing type-2 diabetes medication in UK
(30-May-25 09:13) Relonchem receives marketing authorization for Metformin Hydrochloride 500mg/ 5 ml Oral Solution in UK
(20-May-25 12:49) Board of Marksans Pharma recommends final dividend
(20-May-25 07:46) Marksans Pharma consolidated net profit rises 15.66% in the March 2025 quarter
(19-May-25 13:29) Relonchem receives marketing authorization for Sennosides 7.5 mg tablets
(15-May-25 09:45) Relonchem receives marketing authorization for Gabapentin 50 mg/ml oral solution
(08-May-25 15:09) Marksans Pharma to conduct board meeting
(28-Apr-25 12:58) USFDA concludes inspection of Time-Cap Laboratories' manufacturing facility in New York
(28-Apr-25 11:56) Marksans Pharma gains as USFDA concludes inspection at New York unit

1 2 3 4 5 6 7 8 9 10

Marksans Pharma Ltd